AcuCort (ACUC) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 reached 162 tkr, compared to 0 tkr in Q2 2024, marking the start of commercial sales.

• Net loss after tax for Q2 2025 was -7,569 tkr, widening from -3,803 tkr in Q2 2024.

• Strategic distribution LOIs signed for ZeqmelitⓇ in Germany, five other European countries, and the Middle East.

• ZeqmelitⓇ sales launched in Denmark, expanding Nordic presence.

• Board strengthened with two new members bringing international pharma expertise.

Financial highlights

• Revenue for H1 2025 totaled 162 tkr, up from 0 tkr in H1 2024.

• Net loss after tax for H1 2025 was -14,093 tkr, compared to -7,416 tkr in H1 2024.

• Cash position at June 30, 2025, was 32,444 tkr.

• 1,181 tkr in development costs capitalized in Q2 2025.

• Share capital increased to 85,922 tkr with 234,444,532 shares outstanding.

Outlook and guidance

• Ongoing regulatory filings expected to yield further market approvals outside Scandinavia.

• Sales anticipated to grow as ZeqmelitⓇ becomes more established in the Nordics and new markets.

• Expansion planned into additional European countries and the US, expected to generate further revenue.

• Available liquidity, recent capital raise, and sales expected to cover working capital needs for the next 12 months.